ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

June 27, 2012 — Immune Globulin Infusion (Human), 10% (Gammagard Liquid, Baxter International, Inc), has been approved by the US Food and Drug Administration (FDA) as a treatment for multifocal motor ...

Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q’24 and planned initiation of a Phase 2 trial in Chronic ...

"Multifocal Motor Neuropathy Pipeline Insight"DelveInsight's analysis reveals several companies advancing innovative therapies in the multifocal motor neuropathy clinical pipeline, with groundbreaking ...

Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension ...

(NASDAQ:ARGX) used a fireside chat at the TD Cowen Health Care Conference to outline its near- and longer-term priorities, with incoming CEO Karen Massey emphasizing that the company’s strategy remain ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Argenx is currently conducting a Phase 3 ...

Firm says drug is the first immunoglobulin therapy approved in U.S. for MMN. FDA approved Baxter’s plasma-derived Gammagard Liquid 10% (immune globulin infusion (human)) for improving muscle strength ...

Kieseier and colleagues present a review of the literature on immune-mediated neuropathies, emphasizing the immunopathologic mechanisms underlying these neuropathies. Immune-mediated neuropathies have ...

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal ...